Intuitive Surgical 株価情報 (NASDAQ: ISRG)

Intuitive Surgical (NASDAQ:ISRG) 株価情報

INTUITIVE SURGICAL INC

Intuitive Surgical

Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 9,500 da Vinci systems in hospitals worldwide, with more than 5,500 installations in the US and a growing number in emerging markets.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

ISRG

NFLX

アメリカの株先物は金曜日の朝、低い動きを見せており、投資家の動きも慎重になっている。ウォール街は、オープニングベルの前に、The Procter &amp; Gamble Company（NYSE:PG）が1株あたり1.41ドル、225.41億ドルの売上で四半期決算を発表すると見込んでいます。これはBenzinga Proのデータより明らかになっています。Procter &amp; Gambleの株は、アフターセッションで157.14ドルに0.1％の下落となった。Intuitive Surgical Inc（NASDAQ:ISRG）は、木曜日に第1四半期の決算を予想を上回る結果を発表しました。インチュイティブ・サージカルの株はアフターセッションで3.5％上昇し、385.60ドルで取引されている。アナリストは、American Express Company（NYSE:AXP）が純利益2.95ドル、157.9億ドルの売上で四半期決算を発表すると予想しています。同社は市場がオープンする前に決算を発表します。アメリカン・エキスプレスの株はアフターセッションで、213.90ドルに1.7％下落を記録した。こちらのプレマーケットのカバレッジをチェックNetflix Inc（NASDAQ:NFLX）は第1四半期の楽観的な決算と売上の結果を発表しました。同社は第1四半期に933万人の有料会員を追加し、合計2億6960万人の会員数になりました。Netflixの株はアフターセッションで4.8％下落し、581.49ドルで取引されている。アナリストは、Schlumberger Limited（NYSE:SLB）がオープニングベルの前に1株あたり75セントの四半期利益を、86.9億ドルの売上で発表すると予想しています。SLBの株はアフターセッションで0.5％下落し、50.69ドルで取引されている。

「Netflix（ネットフリックス）、Procter＆Gamble（プロクター＆ギャンブル）」金曜日に注目すべき株式

Intuitive Surgical Inc

Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 20 years by 17.64% on an annualized basis producing an average annual return of 25.97%. Currently, Intuitive Surgical has a market capitalization of $199.56 billion. 
Buying $1000 In ISRG: If an investor had bought $1000 of ISRG stock 20 years ago, it would be worth $100,948.13 today based on a price of $556.78 for ISRG at the time of writing.
<h3>Intuitive Surgical's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747845013_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Intuitive Surgical 20 Years Ago Would Be Worth This Much Today

Intuitive Surgical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has announced a major leadership transition, appointing Dave Rosa as the company&#8217;s next <a href="https://www.benzinga.com/pressreleases/25/05/g45436448/intuitive-announces-ceo-transition-effective-july-1-2025">chief executive officer, effective July 1, 2025</a>.
Rosa, who currently serves as president, will succeed long-serving CEO Gary Guthart, who will become the executive chair of the board.
The move is part of a broader succession strategy as the robotic-assisted surgery pioneer celebrates its 30th anniversary.
As part of the transition, Craig Barratt, the current board chair, will take on the role of lead independent director.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/05/45438765/why-pfizer-is-poised-for-a-strong-comeback-my-top-pick-for-2025" target="_blank" rel="noreferrer noopener">Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025</a>
Guthart, who has led the company for 15 years, will stay on in a senior advisory capacity to support a seamless transition.
Rosa, who joined Intuitive nearly 30 years ago as its ninth employee, has served in multiple roles across engineering, product development, marketing, and commercial operations.
The company recently revealed that the FDA has recently cleared Intuitive&#8217;s da Vinci SP system for transanal local excision/resection, a minimally invasive surgery <a href="https://www.benzinga.com/pressreleases/25/05/g45135080/intuitive-announces-fda-clearance-of-da-vinci-single-port-for-transanal-local-excisionresection" target="_blank" rel="noreferrer noopener">done without abdominal cuts</a>.
This expands the system&#8217;s use in colorectal procedures through natural orifices. It builds on earlier FDA approvals from November 2024 for several transabdominal colorectal surgeries.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, ISRG stock has gained over 39% in the past year.
Investors can gain exposure to the stock via&nbsp;Spinnaker ETF Series Langar Global HealthTech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LGHT#NYSE">LGHT</a>) and&nbsp;iShares U.S. Medical Devices ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHI#NYSE">IHI</a>).
Price Action: ISRG shares are trading lower by 1.69% to $556.38 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45439079/powell-signals-fed-may-shift-its-inflation-strategy-after-5-year-economic-shake-up" target="_blank" rel="noreferrer noopener">Powell Signals Fed May Shift Inflation Strategy After 5 Years Of Economic Upheaval</a></li>
</ul>
Image via Shutterstock

Equities

Health Care

Management

Movers

General

iShares Dow Jones US Medical Devices Index Fund

LGHT

What's Going On With Intuitive Surgical Stock On Thursday?

Intuitive Surgical Current CEO Gary Guthart To Become Executive Chair Of The Board

President Dave Rosa promoted to CEO Current CEO Gary Guthart to become executive chair of Intuitive's board Current Board Chair Craig Barratt to become lead independent director
SUNNYVALE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the promotion of President Dave Rosa to chief executive officer, effective July 1, 2025. At that time, current CEO Gary Guthart will become the executive chair of Intuitive's board of directors, and current Board Chair Craig Barratt will become lead independent director. Guthart will work closely with Rosa to support a smooth transition and will remain with Intuitive in a senior advisory capacity.

Intuitive Promotes President Dave Rosa To CEO, Effective July 1, 2025

Analyst Ratings

Live On CNBC, Stephanie Link Announces Sold Eli Lilly and Co; Announces Bought More Intuitive Surgical

Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 10 years by 15.11% on an annualized basis producing an average annual return of 25.4%. Currently, Intuitive Surgical has a market capitalization of $189.54 billion. 
Buying $100 In ISRG: If an investor had bought $100 of ISRG stock 10 years ago, it would be worth $958.86 today based on a price of $528.83 for ISRG at the time of writing.
<h3>Intuitive Surgical's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746540023_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Intuitive Surgical Stock In The Last 10 Years

<a href="https://x.com/wolfpackreports/status/1919452350432846210?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg" title="https://x.com/wolfpackreports/status/1919452350432846210?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg">https://x.com/wolfpackreports/status/1919452350432846210?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg</a>

CORRECTION: Watching Intuitive Surgical; Wolfpack Research Post On X "If you read our report on how $UFPT's growth story is crumbling because their biggest customer $ISRG is insourcing and ordering from a competitor, then you would know we are long $ISRG ...."

Buybacks

Intuitive Surgical Board On May Increased Authorized Amount Available Under Stock Repurchase Program To Aggregate $4B

Deep-pocketed investors have adopted a bullish approach towards Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ISRG usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Intuitive Surgical. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 62% leaning bullish and 25% bearish. Among these notable options, 3 are puts, totaling $123,976, and 5 are calls, amounting to $239,550.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $460.0 and $640.0 for Intuitive Surgical, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Intuitive Surgical options trades today is 141.71 with a total volume of 126.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Intuitive Surgical's big money trades within a strike price range of $460.0 to $640.0 over the last 30 days.
<h3>Intuitive Surgical Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746115382_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$24.3</td>
<td>$23.4</td>
<td>$23.81</td>
<td>$505.00</td>
<td>$71.4K</td>
<td align="right">248</td>
<td align="right">31</td>
</tr>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$23.2</td>
<td>$22.4</td>
<td>$22.4</td>
<td>$505.00</td>
<td>$58.2K</td>
<td align="right">47</td>
<td align="right">54</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$112.7</td>
<td>$112.0</td>
<td>$112.0</td>
<td>$460.00</td>
<td>$56.0K</td>
<td align="right">64</td>
<td align="right">17</td>
</tr>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$22.6</td>
<td>$22.4</td>
<td>$22.6</td>
<td>$505.00</td>
<td>$40.5K</td>
<td align="right">47</td>
<td align="right">11</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$45.0</td>
<td>$42.3</td>
<td>$45.0</td>
<td>$480.00</td>
<td>$40.5K</td>
<td align="right">195</td>
<td align="right">3</td>
</tr>
</tbody>
</table>

<h3>About Intuitive Surgical</h3>
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 9,500 da Vinci systems in hospitals worldwide, with more than 5,500 installations in the US and a growing number in emerging markets.
Having examined the options trading patterns of Intuitive Surgical, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Intuitive Surgical Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 540,428, the ISRG's price is up by 0.61%, now at $518.95. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 77 days.</li>
</ul>
<h3>Professional Analyst Ratings for Intuitive Surgical</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $575.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Evercore ISI Group keeps a In-Line rating on Intuitive Surgical with a target price of $470. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Intuitive Surgical with a target price of $605. 
&#x2A; An analyst from Truist Securities has decided to maintain their Buy rating on Intuitive Surgical, which currently sits at a price target of $590. 
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Intuitive Surgical, targeting a price of $575. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Intuitive Surgical, maintaining a target price of $635. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Intuitive Surgical, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

A Closer Look at Intuitive Surgical's Options Market Dynamics

Intuitive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that the U.S. Food and Drug Administration (FDA) cleared the da Vinci Single Port (SP) surgical system for transanal local excision/resection, a form of minimally invasive surgery performed through a natural orifice to avoid abdominal surgical incisions for select procedures. This clearance extends the da Vinci SP's capabilities in colorectal surgery, building upon procedures previously cleared by the FDA in November 2024, which include transabdominal procedures - low anterior resection, total mesorectal excision, colectomy, abdominoperineal resection, and sigmoidectomy.
Intuitive engineered the da Vinci SP system to navigate in narrow body cavities requiring precise access, such as lower pelvis and rectal procedures. Its design and architecture support access to rectal anatomy by allowing surgeons to control up to three multi-jointed instruments and a high-definition articulating camera through a single entry point to work freely in the smaller space.
Da Vinci SP also helps mitigate challenges inherent with laparoscopic transanal minimally invasive surgery, such as surgeon ergonomics, reaching lesions in the upper rectum, and working circumferentially, or "upside-down," when needed.

Biotech

Intuitive Announces The U.S. FDA Cleared The Da Vinci Single Port Surgical System For Transanal Local Excision/Resection

Live On CNBC Stephanie Link Announces Bought Intuitive Surgical

Barclays analyst Matt Miksic maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Overweight and lowers the price target from $684 to $635.

Price Target

Barclays Maintains Overweight on Intuitive Surgical, Lowers Price Target to $635

Intuitive Surgical Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) reported first-quarter 2025 revenue of $2.25 billion, beating analyst&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">estimates&nbsp;of $2.19 billion</a>.
Total revenue was up 19% year-over-year as Worldwide da Vinci procedures increased by approximately 17%. The company placed 367 da Vinci surgical systems in the quarter, compared to 313 in the same quarter of the prior year. Intuitive Surgical&#8217;s da Vinci surgical system installed base grew to 10,189 systems as of March 31, <a href="https://www.benzinga.com/pressreleases/25/04/g44936280/intuitive-announces-first-quarter-earnings" target="_blank" rel="noreferrer noopener">up 15% year-over-year</a>.
The company reported first-quarter adjusted earnings of $1.81 per share, beating analyst estimates of $1.72 per share.
Guidance: Intuitive Surgical expects the full-year 2025 worldwide da Vinci procedures to increase by approximately 15%-17%.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44259507/goldman-sachs-gains-confidence-in-market-rebound-upgrades-ge-healthcare-amid-china-recovery-hopes" rel="noreferrer noopener">Goldman Sachs Gains Confidence In Market Rebound, Upgrades GE Healthcare Amid China Recovery Hopes</a>
The company expects a gross profit margin of 65% to 66.5% in 2025, which includes an estimated 1.7% impact from tariffs.
Truist Securities cut the price target from $605 to $590 on Tuesday, while maintaining a Buy rating, due to a lower 2026 estimated EPS, which reflects the incremental tariff impact — and likely leaves room for upside for the robotic-assisted surgery company.
Analyst Richard Newitter writes, &#8220;We think the stock deserves a premium multiple given elevated procedure growth and a new product cycle now in-hand which has potential to drive significant rev and EPS growth acceleration and upside vs. our/CNS thinking into the out-years. Although tariffs remain a NT headwind, it&#8217;s a manageable one in our view that we think investors will gradually begin to look through given ISRG is a leading innovator&#8230;&#8221;
William Blair analyst Brandon Vazquez wrote on Wednesday, &#8220;On macro dynamics, uncertainty around Medicaid, and subsequently capex budgets, will admittedly linger on the stock for the time being.&#8221;
William Blair notes that the management said U.S. capital spending hasn&#8217;t slowed down much yet, but international markets are starting to feel pressure as more money gets shifted toward defense.
Intuitive&#8217;s leasing model is helping hospitals manage tight budgets. Still, investors are keeping a close eye on the situation—especially with possible Medicaid cuts that could tighten hospital finances. While it&#8217;s hard to predict if those cuts will happen due to the current political climate, they could have a huge impact, as around 16% of U.S. adults rely on Medicaid.
Stifel analyst on Tuesday wrote, &#8220;Our procedure growth focus reminds us that system placements drive future procedures, top-line growth, and future margin expansion&#8230;and this 1Q25 procedure growth was an encouraging start to the year. While ISRG was pressured in after-hours trading, we expect investors will find a lot to like as they review further Intuitive&#8217;s 1Q25 results and key performance metrics.&#8221;
Analyst Rick Wise says the $9.1 billion cash position and zero debt offer excellent balance sheet flexibility and the opportunity to buy back shares. Stifel maintains a price target of $670 <a href="https://www.benzinga.com/quote/ISRG/analyst-ratings" target="_blank" rel="noreferrer noopener">with a Buy rating</a>.
Price Action: ISRG stock is up 2.47% to $490.58 at last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44955951/ge-vernova-can-mitigate-tariff-and-inflation-concerns-after-strong-q1-sticks-to-annual-outlook" target="_blank" rel="noreferrer noopener">GE Vernova Can Mitigate Tariff And Inflation Concerns After Strong Q1, Sticks To Annual Outlook</a></li>
</ul>

Analyst Color

Large Cap

Guidance

Analysts Remain Bullish On Intuitive Surgical Despite Macro Uncertainty

Risk-on sentiment dominated Wall Street on Wednesday, as upbeat earnings reports and conciliatory messages from the Trump administration h<a href="https://www.benzinga.com/markets">elped lift investor confidence.</a>
The administration eased market fears on two major fronts that have recently weighed heavily on sentiment. On the trade front, tensions with China appeared to thaw, with reports suggesting the White House is considering reducing tariffs on certain categories of goods.
U.S. Treasury Secretary Scott Bessent added fuel to the rally, stating U.S.-China tariffs are unsustainable and will likely need to be lowered to facilitate meaningful negotiations.
Meanwhile, President Donald Trump offered an abrupt shift in tone toward Federal Reserve Chair Jerome Powell, saying he has no intention to fire him, a remark that helped calm concerns over political interference in monetary policy.
By midday in New York, the S&amp;P 500 was up by nearly 2%, though it had earlier climbed even higher. The Nasdaq 100 outperformed with a 2.5% gain, driven by strength in Magnificent Seven stocks.
Trump's pivot on Powell pushed Treasury yields lower across the curve, with the 30-year yield falling five basis points to 4.83%, after briefly topping 4.90% the previous day.
On the macro front, flash Purchasing Managers&#8217; Index surveys revealed slowing growth momentum in the U.S. economy, as the services sector decelerated sharply following the impact <a href="https://www.benzinga.com/government/regulations/25/04/44952395/us-business-activity-growth-slows-in-april-as-services-suffer-tariff-shock-markets-rally-as-trade-war-cools">of recent tariff shocks.</a>
The U.S. dollar strengthened, while gold plunged 2.6%, heading for its worst session since November.
Oil prices dropped more than 2% following speculation that OPEC+ may announce a new output hike as early as next month.
Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) held steady around $93,000.
<h1 class="wp-block-heading">Wednesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg</td>
<td>1-day %</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,732.09</td>
<td>+455.68</td>
<td>2.5%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,926.45</td>
<td>+37.40</td>
<td>2.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,384.67</td>
<td>+96.91</td>
<td>1.8%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,724.87</td>
<td>+537.89</td>
<td>1.4%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:35 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 1.9% to $537.35.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 1.4% to $397.79.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rallied 2.7% to $456.50.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) soared 2.1% to $191.47.</li>
<li>The&nbsp;Technology&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up 3.44%; the&nbsp;Consumer Staples&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) lagged, down 1.2%.</li>
</ul>
<h1 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h1>
<ul>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) jumped 6.6% despite falling short on both earnings and revenue expectations, as CEO Elon Musk reassured investors by pledging to scale back his involvement with DOGE and refocus on the company.</li>
</ul>
Other stocks reacting to earnings report included: 
<ul>
<li>Intuitive Surgical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>): up 2.8%</li>
<li>Chubb Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>): down 2.6%</li>
<li>Capital One Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>): up 4.6%</li>
<li>Steel Dynamics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>): up 4.7%</li>
<li>EQT Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>): up 3%</li>
<li>Packaging Corporation of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>): down 1.7%</li>
<li>Baker Hughes Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>): down 4.3%</li>
<li>Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>): down 14.4%​</li>
<li>Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>): down 0.5%</li>
<li>Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>): up 2.6%</li>
<li>NextEra Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>): up 1%</li>
<li>Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>): up 4.8%</li>
<li>General Dynamics Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>): down 3.4%</li>
<li>Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>): up 5.7%</li>
<li>Norfolk Southern Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>): up 1.4%</li>
<li>CME Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>): down 3.8%</li>
<li>TE Connectivity Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEL#NYSE">TEL</a>): up 2.7%</li>
<li>Amphenol Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>): up 9.9%</li>
<li>AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>): up 0.8%</li>
<li>Old Dominion Freight Line, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>): up 1.3%</li>
<li>Westinghouse Air Brake Technologies Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>): up 7.2%</li>
<li>Masco Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>): down 2.1%</li>
<li>Avery Dennison Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>): down 2.4%</li>
<li>Lennox International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>): down 8.2%</li>
<li>GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>): up 5.2%</li>
<li>Teledyne Technologies Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>): down 1.7%</li>
<li>Otis Worldwide Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTIS#NYSE">OTIS</a>): down 6%​</li>
</ul>
<ul>
<li>Stocks slated to report earnings after the bell include Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>), O'Reilly Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>), Raymond James Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>), Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), Texas Instruments Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>), FirstEnergy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FE#NYSE">FE</a>), ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>), Lam Research Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>), Resmed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>), Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>), International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>), Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), Rollins Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROL#NYSE">ROL</a>), United Rentals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>), Tyler Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>), Edwards Lifesciences Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), Las Vegas Sands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>), and Alaska Air Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>).</li>
</ul>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44948932/goldman-sachs-backs-copper-tariff-trade-if-trump-slaps-25-duty-on-us-imports">Goldman Sachs Backs &#8216;Copper Tariff Trade&#8217; If Trump Slaps 25% Duty On US Imports</a></li>
</ul>
Photo: Shutterstock

Government

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Economics

Federal Reserve

Tech

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

ENPH

LRCX

ODFL

ORLY

OTIS

STLD

TSLA

Select Sector SPDR-Consumer Discretionary

Stocks Surge On China Tariff Hopes, Tesla Jumps, Gold Loses Shine: What's Driving Markets Wednesday?

Intuitive Surgical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) reported better-than-expected first-quarter financial results <a href="https://www.benzinga.com/quote/ISRG/earnings">Tuesday after the bell</a>.
Intuitive Surgical reported first-quarter revenue of $2.25 billion, beating analyst estimates of $2.19 billion, according to Benzinga Pro. The robotic-assisted surgery company reported first-quarter adjusted earnings of $1.81 per share, beating analyst estimates of $1.72 per share.
"Core measures of our business were healthy this quarter, and we are pleased by continued customer adoption of our platforms, including da Vinci 5. As we look ahead, we remain focused on enabling our customers to deliver on their goals: better patient outcomes, improved patient and care team experiences, lower total cost to treat, and increased access to care," said Gary Guthart, CEO of Intuitive Surgical.
Intuitive Surgical expects full-year 2025 worldwide da Vinci procedures to increase approximately 15% to 17%. The company expects gross profit margin to be between 65% and 66.5% of revenue in 2025, which includes an estimated 1.7% impact from tariffs.
Intuitive Surgical shares gained 3% to trade at $492.96 on Wednesday.
These analysts made changes to their price targets on Intuitive Surgical following earnings announcement.
<ul>
<li>Baird analyst David Rescott maintained Intuitive Surgical with an Outperform rating and lowered the price target from $600 to $575.</li>
<li>Evercore ISI Group analyst Vijay Kumar maintained the stock with an In-Line rating and lowered the price target from $510 to $470.</li>
<li>Piper Sandler analyst Adam Maeder maintained Intuitive Surgical with an Overweight rating and lowered the price target from $670 to $575.</li>
<li>Truist Securities analyst Richard Newitter maintained the stock with a Buy rating and cut the price target from $605 to $590.</li>
<li>RBC Capital analyst Shagun Singh maintained Intuitive Surgical with an Outperform rating and lowered the price target from $630 to $605..</li>
</ul>
Considering buying ISRG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23130534/image-1-27-1024x585.png" alt="" class="wp-image-884798" style="width:582px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23130534/image-1-27-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23130534/image-1-27-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23130534/image-1-27-768x438.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23130534/image-1-27.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44950904/tesla-to-303-here-are-10-top-analyst-forecasts-for-wednesday">Tesla To $303? Here Are 10 Top Analyst Forecasts For Wednesday</a> </li>
</ul>
Photo via Shutterstock

These Analysts Lower Their Forecasts On Intuitive Surgical After Q1 Earnings

RBC Capital analyst Shagun Singh maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Outperform and lowers the price target from $630 to $605.

RBC Capital Maintains Outperform on Intuitive Surgical, Lowers Price Target to $605

Truist Securities analyst Richard Newitter maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Buy and lowers the price target from $605 to $590.

Truist Securities Maintains Buy on Intuitive Surgical, Lowers Price Target to $590

Piper Sandler analyst Adam Maeder maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Overweight and lowers the price target from $670 to $575.

Piper Sandler Maintains Overweight on Intuitive Surgical, Lowers Price Target to $575

Evercore ISI Group analyst Vijay Kumar maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a In-Line and lowers the price target from $510 to $470.

Evercore ISI Group Maintains In-Line on Intuitive Surgical, Lowers Price Target to $470

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/04/22/final-trades-3m-abbvie-salesforce-and-intuitive-surgical.html">Halftime Report Final Trades</a>,&#8221; Joshua Brown, CEO and co-founder, Ritholtz Wealth Management, said he is staying long on 3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>).
Supporting his view, 3M reported better-than-expected first-quarter financial results on Tuesday. The company reported net sales of $5.95 billion, a 1.0% decline year-over-year (Y/Y), beating the consensus of $ 5.78 billion. Adjusted EPS was $1.88, up 10% Y/Y, beating the <a href="https://in.benzinga.com/news/earnings/25/04/44921668/3m-stock-surges-after-q1-beat-as-2025-outlook-flags-tariff-pressure">consensus of $1.77</a>.
Jim Lebenthal of Cerity Partners picked AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) as his final trade.
Lending support to his choice, Cantor Fitzgerald analyst Carter Gould initiated coverage of AbbVie on Tuesday with an Overweight rating and a price target of $210.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Rob Sechan of New Edge Capital Group named Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) as his final trade.
Guggenheim analyst John Difucci upgraded Salesforce from Sell to Neutral on Monday.
Stephanie Link of Hightower picked Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) as her final trade.
On the earnings front, Intuitive Surgical reported first-quarter revenue of $2.25 billion on Tuesday, beating analyst estimates of $2.19 billion. The robotic-assisted surgery company reported first-quarter adjusted earnings of $1.81 per share, beating analyst estimates of $1.72 per share.
Price Action:
<ul>
<li>3M shares jumped 8.1% to close at $136.33 on Tuesday.</li>
<li>AbbVie gained 2.1% to close at $173.78 during Tuesday's session.</li>
<li>Salesforce shares rose 3% to close at $243.39 on Tuesday.</li>
<li>Intuitive Surgical shares climbed 2.2% to settle at $478.74 during the session.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44920101/top-2-tech-and-telecom-stocks-you-may-want-to-dump-this-quarter">Top 2 Tech And Telecom Stocks You May Want To Dump This Quarter</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Media

ABBV

Salesforce, AbbVie, Intuitive Surgical And An Industrial Stock On CNBC's 'Final Trades'

Press Releases

Intuitive Announces $45 Million Donation to the Intuitive Foundation to Promote Health and Advance Education

Astera Labs Appoints Dr. Craig Barratt to Board of Directors

Mutual Funds

DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

Peer-Reviewed Studies on Intuitive's Force Feedback Technology Demonstrate its Potential to Reduce Force on Tissue and Enhance Surgeon Performance

Small Cap

Opinion

AI-Powered Service Robots Redefine Hospitality as Industry Innovators Lead the Charge

U.S. FDA clears first stapler designed for single-port robotic surgery

New Research Explores Access to Minimally Invasive Care and the Impact of Robotic-Assisted Surgery

Intuitive Announces First Quarter Earnings

Intuitive Announces FDA Clearance of da Vinci Single Port for Transanal Local  Excision/Resection

Intuitive Announces CEO Transition Effective July 1, 2025

ALAB

AMBC

AMZN

BBWI

CLSK

DASH

FLGT

FRPT

GDOT

GPRE

HAIN

HIMS

KTOS

MATV

NEOG

NGTF

PLTR

SATS

SERV

SPGI

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

Barclays

RBC Capital

Truist Securities

Piper Sandler

Evercore ISI Group

Untitled design - 2024-12-10T185819.364

Movers & Shakers

MBOT

Palm-Sized Innovation: How Microbot Medical Is Helping Redefine Surgical Robotics

Comments

Intuitive Surgical

ニュース

パートナーシップ

ベンジンガ・グローバル